AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32903275 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc Blue
Number of subjects: 180
Study 32903275 — intervention group
Group type: EXPERIMENTAL
Intervention: TF adaptive
Number of subjects: 180
Study 32903275 — intervention group
Group type: EXPERIMENTAL
Intervention: 2Shape
Number of subjects: 180
Study 32903275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 36067479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion and chorion allograft (dHACA) plus standard of care (weekly and biweekly applications)
Number of subjects: 60
Study 36067479 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 60
Study 36067479 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including dHACA and standard of care)
Number of subjects: 60
Study 36067479 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 60
Study 33617972 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement combination (Boswellia serrata extract 250 mg/day, pine bark extract 100 mg/day, methylsulfonylmethane 1,500 mg/day, curcumin 168 mg/day)
Number of subjects: 106
Study 33617972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 33617972 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement combination
Number of subjects: 106
Study 33484397 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-delivered therapy (5-week duration)
Number of subjects: 73
Study 33484397 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 73
Study 33678535 — intervention group
Group type: COMPARATOR
Intervention: Natural menstrual cycle (placebo condition)
Number of subjects: 78
Study 33678535 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive pill (OCP condition)
Number of subjects: 78
Study 33678535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low estradiol to progesterone ratio and testosterone concentrations
Number of subjects: 78
Study 33678535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dfo
Number of subjects: 78
Study 35194446 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir (ATZ/RTV)
Number of subjects: 132
Study 35194446 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (LPV/RTV)
Number of subjects: 132
Study 34996819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (16 sessions over 12 weeks, plus 4 telephone follow-ups)
Number of subjects: 100
Study 34996819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 35579951 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (three times a week, 20-35 min per session at 55%-70% of maximum heart rate)
Number of subjects: 39
Study 35579951 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 39
Study 33675447 — intervention group
Group type: COMPARATOR
Intervention: Resting heart rate (RHR) > 100 beats per minute
Number of subjects: 1259485
Study 33675447 — intervention group
Group type: COMPARATOR
Intervention: IQ above the highest tertile
Number of subjects: 1259485
Study 33675447 — intervention group
Group type: COMPARATOR
Intervention: Physical fitness, BMI, blood pressure, or stress resilience
Number of subjects: 1259485
Study 33675447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis for IQ
Number of subjects: 1259485
Study 33675447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis for RHR
Number of subjects: 1259485
Study 32696472 — intervention group
Group type: EXPERIMENTAL
Intervention: Online support
Number of subjects: 128
Study 32696472 — intervention group
Group type: COMPARATOR
Intervention: Onsite support
Number of subjects: 128
Study 33971152 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine-PET/CT
Number of subjects: 165
Study 33971152 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 165
Study 33971152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165
Study 32449063 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptome assembly and annotation
Number of subjects: 90
Study 32449063 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite marker development
Number of subjects: 90
Study 34319998 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticoagulants (PAC)
Number of subjects: 95
Study 34319998 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic anticoagulants (no PAC)
Number of subjects: 95
Study 34319998 — intervention group
Group type: EXPERIMENTAL
Intervention: S/P-albumin <20g/L
Number of subjects: 95
Study 34319998 — intervention group
Group type: COMPARATOR
Intervention: S/P-albumin ≥20g/L
Number of subjects: 95
Study 32303003 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor skills
Number of subjects: 600
Study 32303003 — intervention group
Group type: EXPERIMENTAL
Intervention: Object control skills
Number of subjects: 600
Study 32303003 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI, object control skills, and engagement
Number of subjects: 600
Study 32303003 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor engagement
Number of subjects: 600
Study 32303003 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perception
Number of subjects: 600
Study 36007156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 338
Study 36007156 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 338
Study 33235154 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course induction chemotherapy (2 cycles of cisplatin 20 mg/m2 plus etoposide 40 or 100 mg/m2 for 5 days) followed by low-dose radiotherapy (dose: 2340 cGy) without a tumor bed boost
Number of subjects: 24
Study 33235154 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy without a tumor bed boost
Number of subjects: 24
Study 32975835 — intervention group
Group type: COMPARATOR
Intervention: 10 µg LSD
Number of subjects: 23
Study 32975835 — intervention group
Group type: COMPARATOR
Intervention: 20 µg LSD
Number of subjects: 23
Study 32975835 — intervention group
Group type: COMPARATOR
Intervention: 5 µg LSD
Number of subjects: 23
Study 32975835 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 µg, 10 µg, 20 µg LSD
Number of subjects: 23
Study 33389959 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic insulin users
Number of subjects: 60656
Study 33389959 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic insulin users (male)
Number of subjects: 60656
Study 33389959 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic insulin users (age 40-59)
Number of subjects: 60656
Study 33389959 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic insulin users (2 to 4 years of morbidity)
Number of subjects: 60656
Study 32432990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based strengths practice (MBSP)
Number of subjects: 52
Study 32432990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 32524991 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 265
Study 32524991 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 265
Study 34435738 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education program (8-week duration)
Number of subjects: 136
Study 34435738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 136
Study 33946428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet (FMD) bar
Number of subjects: 0
Study 33946428 — intervention group
Group type: COMPARATOR
Intervention: Breakfast group (control)
Number of subjects: 0
Study 32013276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) on thoracic dorsal root ganglion (DRG)
Number of subjects: 64
Study 32013276 — intervention group
Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF) on thoracic paravertebral nerve (PVN)
Number of subjects: 64
Study 36454874 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms measured with the Short Mood and Feelings Questionnaire (SMFQ), positive screen if scored ≥12
Number of subjects: 2120
Study 36454874 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents in South Africa
Number of subjects: 2120
Study 36454874 — intervention group
Group type: EXPERIMENTAL
Intervention: Female adolescents
Number of subjects: 2120
Study 36454874 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents who reported ever having sex and being forced into sex
Number of subjects: 2120
Study 36454874 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents who self-reported to ever having had sex and used alcohol/drugs during their last sexual encounter
Number of subjects: 2120
Study 36454874 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents who reported using a condom during their last sexual encounter
Number of subjects: 2120
Study 34294126 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cultural experience named Ways of Being
Number of subjects: 0
Study 34294126 — intervention group
Group type: COMPARATOR
Intervention: Typical museum website (the Ashmolean Museum)
Number of subjects: 0
Study 33290971 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol capsules (1.5 g/day)
Number of subjects: 31
Study 33290971 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil capsules (2 g/day)
Number of subjects: 31
Study 32349789 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-delivered home-based screening
Number of subjects: 900
Study 32349789 — intervention group
Group type: COMPARATOR
Intervention: Navigation to care by a CHW
Number of subjects: 900
Study 35671976 — intervention group
Group type: EXPERIMENTAL
Intervention: Integral approach group (IA)
Number of subjects: 80
Study 35671976 — intervention group
Group type: COMPARATOR
Intervention: mHealth alone (Control group - CG)
Number of subjects: 80
Study 33306985 — intervention group
Group type: EXPERIMENTAL
Intervention: G614 pseudovirus
Number of subjects: 0
Study 33306985 — intervention group
Group type: EXPERIMENTAL
Intervention: RBD monoclonal antibodies
Number of subjects: 0
Study 33306985 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent sera from people infected with either form of the virus
Number of subjects: 0
Study 33306985 — intervention group
Group type: EXPERIMENTAL
Intervention: D614G mutation
Number of subjects: 0
Study 35294543 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser tonsillotomy under local anesthesia
Number of subjects: 101
Study 35294543 — intervention group
Group type: COMPARATOR
Intervention: Conventional tonsillectomy with general anesthesia
Number of subjects: 101
Study 34365971 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of a clinical focus hypothesis
Number of subjects: 111
Study 34365971 — intervention group
Group type: COMPARATOR
Intervention: No focus hypothesis
Number of subjects: 111
Study 34365971 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall detection of epileptogenic lesions
Number of subjects: 111
Study 34365971 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term epilepsy associated tumors
Number of subjects: 111
Study 34365971 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliotic scar, hemosiderin or cavernoma
Number of subjects: 111
Study 34365971 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal sclerosis or limbic encephalitis
Number of subjects: 111
Study 34365971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodular heterotopia
Number of subjects: 111
Study 34365971 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal cortical dysplasias
Number of subjects: 111
Study 34560708 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPS intervention
Number of subjects: 32
Study 34560708 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 32
Study 33843366 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI) preoperative and postoperative assessment
Number of subjects: 181
Study 33843366 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Dimensional Voice Program analysis
Number of subjects: 181
Study 33843366 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 randomly selected patients without vocal fold paresis or paralysis)
Number of subjects: 181
Study 35672853 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART
Number of subjects: 203
Study 35672853 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz-based ART
Number of subjects: 203
Study 32529506 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week HIIT intervention (n=21)
Number of subjects: 41
Study 35491320 — intervention group
Group type: COMPARATOR
Intervention: Standard information on side-effects (control)
Number of subjects: 160
Study 35491320 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard information with additional information about CRCS (information)
Number of subjects: 160
Study 35491320 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and additional information with a subsequent self‐affirmative text (information+SA)
Number of subjects: 160
Study 34709363 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 312
Study 34709363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 312
Study 34709363 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept or Bevacizumab
Number of subjects: 312
Study 35972446 — intervention group
Group type: EXPERIMENTAL
Intervention: Blimp balloon
Number of subjects: 126
Study 35972446 — intervention group
Group type: COMPARATOR
Intervention: Low-profile balloon
Number of subjects: 126
Study 35972446 — intervention group
Group type: EXPERIMENTAL
Intervention: Blimp balloon after LP balloon failure
Number of subjects: 126
Study 35972446 — intervention group
Group type: COMPARATOR
Intervention: Low-profile balloon after Blimp balloon failure
Number of subjects: 126
Study 35972446 — intervention group
Group type: EXPERIMENTAL
Intervention: Blimp balloon overall success after guide catheter extension
Number of subjects: 126
Study 35972446 — intervention group
Group type: COMPARATOR
Intervention: Low-profile balloon overall success after guide catheter extension
Number of subjects: 126
Study 33507350 — intervention group
Group type: EXPERIMENTAL
Intervention: Scroll reconstruction
Number of subjects: 28
Study 33507350 — intervention group
Group type: COMPARATOR
Intervention: No scroll reconstruction (Control)
Number of subjects: 28
Study 33485377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for not smoking cigarettes (self-reported)
Number of subjects: 1559
Study 35171823 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced ETTCP
Number of subjects: 1671
Study 35171823 — intervention group
Group type: COMPARATOR
Intervention: Unadjusted ETTCP
Number of subjects: 1671
Study 34479573 — intervention group
Group type: EXPERIMENTAL
Intervention: gLiFE
Number of subjects: 309
Study 34479573 — intervention group
Group type: COMPARATOR
Intervention: LiFE
Number of subjects: 309
Study 32740819 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced videofluoroscopy (VFS)
Number of subjects: 21
Study 32740819 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced 3-T MRI
Number of subjects: 21
Study 33028566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (20 mg/kg for 3 days, followed by 10 mg/kg for a further 7 days)
Number of subjects: 796
Study 33028566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 796
Study 33028566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin
Number of subjects: 796
Study 33028566 — intervention group
Group type: COMPARATOR
Intervention: Intravenous azithromycin and placebo
Number of subjects: 796
Study 35652747 — intervention group
Group type: COMPARATOR
Intervention: Standard procedures
Number of subjects: 3465
Study 35652747 — intervention group
Group type: EXPERIMENTAL
Intervention: Additive Holter electrocardiogram
Number of subjects: 3465
Study 34969074 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA admission avoidance hospital at home (HAH)
Number of subjects: 700
Study 34969074 — intervention group
Group type: COMPARATOR
Intervention: Admission to hospital
Number of subjects: 700
Study 32936837 — intervention group
Group type: EXPERIMENTAL
Intervention: AMBER care bundle
Number of subjects: 38
Study 35365148 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intake group (400 kcal)
Number of subjects: 146
Study 35365148 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose intake group (75 g glucose)
Number of subjects: 146
Study 35365148 — intervention group
Group type: COMPARATOR
Intervention: Fasting group
Number of subjects: 146
Study 35610083 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary intervention including nutrition education using a smartphone game, aerobic exercise, and cognitive behavioral therapy (CBT)
Number of subjects: 62
Study 35610083 — intervention group
Group type: COMPARATOR
Intervention: Usual traditional nutritional education
Number of subjects: 62
Study 35610083 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary intervention
Number of subjects: 62
Study 32046467 — intervention group
Group type: EXPERIMENTAL
Intervention: lncRNA and mRNA expression profiling
Number of subjects: 2
Study 32046467 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of expression levels
Number of subjects: 2
Study 32046467 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional analysis of lncRNAs
Number of subjects: 2
Study 32046467 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional analysis of mRNAs
Number of subjects: 2
Study 34465443 — intervention group
Group type: EXPERIMENTAL
Intervention: 2020 San Francisco sugary drink warning label
Number of subjects: 2160
Study 34465443 — intervention group
Group type: COMPARATOR
Intervention: Control label ('Always read the Nutrition Facts Panel')
Number of subjects: 2160
Study 33991353 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut bead‐based epitope assay (peanut BBEA)
Number of subjects: 299
Study 33991353 — intervention group
Group type: COMPARATOR
Intervention: Existing diagnostic tests for peanut allergy (including skin prick testing, peanut sIgE, and peanut component sIgE testing)
Number of subjects: 299
Study 32443319 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA/riboflavin cross-linking (0.1% riboflavin solution for 10 minutes)
Number of subjects: 49
Study 32443319 — intervention group
Group type: COMPARATOR
Intervention: Soaked in 0.1% riboflavin for 10 minutes (B2 group)
Number of subjects: 49
Study 32443319 — intervention group
Group type: COMPARATOR
Intervention: Control group (directly into corneal preservation solution)
Number of subjects: 49
Study 35837807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 189
Study 35837807 — intervention group
Group type: COMPARATOR
Intervention: Natural course (NC)
Number of subjects: 189
Study 35837807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) in AIDP subtype
Number of subjects: 189
Study 35837807 — intervention group
Group type: COMPARATOR
Intervention: Natural course (NC) in AIDP subtype
Number of subjects: 189
Study 35837807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) in AMAN subtype
Number of subjects: 189
Study 35837807 — intervention group
Group type: COMPARATOR
Intervention: Natural course (NC) in AMAN subtype
Number of subjects: 189
Study 34531963 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 57
Study 34531963 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (control)
Number of subjects: 57
Study 35909384 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake-prone positioning (APP)
Number of subjects: 82
Study 35909384 — intervention group
Group type: COMPARATOR
Intervention: Conventional positioning interventions (Control)
Number of subjects: 82
Study 33436336 — intervention group
Group type: EXPERIMENTAL
Intervention: Expander Prosthesis (EP)
Number of subjects: 73
Study 33436336 — intervention group
Group type: COMPARATOR
Intervention: DIEP flap
Number of subjects: 73
Study 33222598 — intervention group
Group type: EXPERIMENTAL
Intervention: High Lp(a) group (≥60 mg/dL)
Number of subjects: 3943
Study 33222598 — intervention group
Group type: COMPARATOR
Intervention: Low Lp(a) group (<60 mg/dL)
Number of subjects: 3943
Study 33222598 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quintiles of Lp(a)
Number of subjects: 3943
Study 35970199 — intervention group
Group type: COMPARATOR
Intervention: Placement of intrauterine device at 2-4 weeks after abortion
Number of subjects: 240
Study 35970199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study 34161899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric-onset Multiple Sclerosis (POMS)
Number of subjects: 30
Study 34161899 — intervention group
Group type: COMPARATOR
Intervention: Theory of Mind (ToM) tests
Number of subjects: 30
Study 34161899 — intervention group
Group type: COMPARATOR
Intervention: ToM performance analysis by age of disease onset
Number of subjects: 30
Study 36115963 — intervention group
Group type: EXPERIMENTAL
Intervention: TransformUs intervention, delivered by teachers with varying levels of implementation (Low < 33%, Moderate 33-67%, High > 67%).
Number of subjects: 407
Study 36115963 — intervention group
Group type: EXPERIMENTAL
Intervention: TransformUs intervention, delivered by teachers.
Number of subjects: 407
Study 36115963 — intervention group
Group type: EXPERIMENTAL
Intervention: TransformUs intervention, teachers' implementation level.
Number of subjects: 407
Study 36115963 — intervention group
Group type: EXPERIMENTAL
Intervention: TransformUs intervention, overall program evaluation.
Number of subjects: 407
Study 32781894 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation
Number of subjects: 603
Study 32781894 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation
Number of subjects: 603
Study 34888612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 109
Study 34888612 — intervention group
Group type: COMPARATOR
Intervention: Esmolol (E)
Number of subjects: 109
Study 34888612 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study 35953729 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0